A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia
A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia
复制标题
DOI：
10.1159/000102570
复制
发表时间：
2007-01-01
影响因子：
2.4
通讯作者：
Sakurai, Emilia
中科院分区：
文献类型：
--
作者：
de Vasconcelos Cunha, Ulisses Gabriel;Rocha, Fabio Lopes;Sakurai, Emilia
背景/目的：评价文拉法辛治疗痴呆性抑郁症的疗效和安全性。方法：31名患有痴呆症和重度抑郁症的门诊患者参加了这项随机、双盲、安慰剂对照、为期6周、剂量灵活的临床试验。筛查方法为康奈尔痴呆量表、抑郁与痴呆DSM-IV和简易精神状态检查。结果测量指标为反应率、蒙哥马利-阿斯伯格抑郁量表和临床总体印象。结果：在安慰剂组和文拉法辛组中，患者被定义为蒙哥马利-阿斯伯格抑郁评定量表有效者的百分比大致相同。临床总体印象显示，两组之间没有显著差异。辍学的原因在两组人中显示出了边缘意义。文拉法辛治疗组和安慰剂治疗组之间的不良事件发生率在统计学上没有显著差异。结论：我们的数据不支持文拉法辛改善老年痴呆患者情绪的假设。版权所有(C)2007 S.Karger AG，巴塞尔。
Background/Aims: To evaluate the efficacy and safety of venlafaxine in the treatment of major depression in dementia. Methods: Thirty-one outpatients who had dementia and major depression participated in this randomized, double-blind, placebo-controlled, 6-week, flexible dose clinical trial. The screening measures were Cornell Scale for depression in dementia, DSM-IV for depression and dementia and Mini-Mental State Examination. The outcome measures were response rate, Montgomery-Asberg Depression Rating scale and Clinical Global Impressions. Results: The percentage of patients defined as Montgomery-Asberg Depression Rating scale responders was approximately the same in the placebo and in the venlafaxine groups. Clinical Global Impressions showed no significant difference between the groups. The reasons for dropouts show borderline significance between the two groups. There was no statistically significant difference in the incidence of adverse events between the venlafaxine and placebo-treated groups. Conclusions: Our data do not support the hypothesis that venlafaxine improves mood in elderly demented patients. Copyright (c) 2007 S. Karger AG, Basel.